Loading
No insider purchase over the last 90 days. The latest, by Wang Weidong, was filed 15 Jun 2026.
RemeGen Co., Ltd. - H Shares is a listed company. Filings by its managers are published through HKEX. 7 insiders have disclosed 40 filings since 24 October 2025.
Both sides are active: 26 purchases and 5 sales worth €461k, from 5 insiders and 3 insiders respectively. The amount is not disclosed for 26 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 5 senior executives among the declarants. At €198k, the sale published on 24 July 2026 by Fang Jianmin is the largest of the period (0.0040% of market cap).
With 40 filings in twelve months, the company is more active than the median of 4 filings across the 1,315 companies we follow on the same exchange. Since 2026, the database holds 26 purchases and 5 sales by insiders of the company.
The clock since the last published purchase (15 June 2026) now reads 131 days. The median gap between a trade and its publication by HKEX is 6 days. The shorter that gap, the sooner other investors can see what insiders have done.
Source: insider filings from HKEX. Past trades are no guide to future returns.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
25 of 49 declarations
RemeGen Co., Ltd. is a Chinese biopharmaceutical company focused on the research and development of innovative treatments for cancer and other autoimmune diseases. It is listed on the H-share market.